Aug. 24 at 8:51 PM
Azenta disclosed a sudden leadership change after CEO John Marotta resigned as president, CEO and board member, effective immediately. The announcement triggered a sharp decline in the stock as investors reacted to the unexpected departure and uncertainty surrounding the company’s next phase.
Azenta appointed Dr. Martin Madaus as interim CEO. A current board member with more than 30 years of experience in diagnostics and life-science tools, Madaus also serves as a Senior Operating Executive at The Carlyle Group. The company hired Heidrick & Struggles to search for a permanent replacement, potentially extending near-term uncertainty.
Azenta also expects a roughly
$3 million one-time consulting charge to impact Q4 adjusted EBITDA, although it reaffirmed its quarterly revenue guidance. The leadership shakeup comes after the stock more than doubled from its May 2026 multi-year lows, increasing the risk of a correction.
$AZTA